The groundbreaking rise of Viagra has consistently remained a benchmark of pharmaceutical success, however its future within the broader sector now presents questions about potential returns . Alternative versions are undercutting market share, causing worries that betting on companies heavily reliant to Viagra's previous influence could be a probl